Cargando…
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
Ewing sarcoma is the second most common pediatric bone tumor, with three cases per million worldwide. In clinical terms, Ewing sarcoma is an aggressive, rapidly fatal malignancy that mainly develops not only in osseous sites (85%) but also in extra-skeletal soft tissue. It spreads naturally to the l...
Autores principales: | Redini, Françoise, Heymann, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688361/ https://www.ncbi.nlm.nih.gov/pubmed/26779435 http://dx.doi.org/10.3389/fonc.2015.00279 |
Ejemplares similares
-
Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013) -
Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
por: Jacques, Camille, et al.
Publicado: (2016) -
The Challenges of Detecting Circulating Tumor Cells in Sarcoma
por: Tellez-Gabriel, Marta, et al.
Publicado: (2016) -
EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma
por: Cidre-Aranaz, Florencia, et al.
Publicado: (2015) -
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration
por: Odri, Guillaume, et al.
Publicado: (2014)